

Serge A Jabbour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4349310/publications.pdf>

Version: 2024-02-01

33
papers

1,848
citations

394421

19
h-index

454955

30
g-index

35
all docs

35
docs citations

35
times ranked

2234
citing authors

#	ARTICLE	IF	CITATIONS
1	Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1187-1196.	4.4	12
2	Assessing the impact of medically tailored meals and medical nutrition therapy on type 2 diabetes: Protocol for Project MiNT. <i>Contemporary Clinical Trials</i> , 2021, 108, 106511.	1.8	5
3	Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 393-403.	4.4	53
4	Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 99-106.	4.4	5
5	Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial. <i>Diabetes Care</i> , 2020, 43, 2528-2536.	8.6	30
6	Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel design, open-label, Phase 3 trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 957-968.	4.4	4
7	Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease. <i>Diabetes Therapy</i> , 2020, 11, 1467-1480.	2.5	4
8	Scleromyxedema in a patient with thyroid disease: an atypical case or a case for revised criteria?. <i>Cutis</i> , 2020, 105, E6-E10.	0.3	0
9	Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. <i>Diabetes Care</i> , 2019, 42, 1464-1472.	8.6	5
10	Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2019, 180, 186-203.	1.7	86
11	Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1602-1614.	4.4	54
12	Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1520-1525.	4.4	23
13	Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1515-1519.	4.4	39
14	Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 667-671.	4.4	107
15	Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 620-628.	4.4	121
16	Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. <i>Diabetes Care</i> , 2018, 41, 2136-2146.	8.6	73
17	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the Tj ETQq1 1 0.784314 rgBTJ /Overlock	8.6	190
18	Durability of response to dapagliflozin: a review of long-term efficacy and safety. <i>Current Medical Research and Opinion</i> , 2017, 33, 1685-1696.	1.9	11

#	ARTICLE	IF	CITATIONS
19	Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 1004-1016.	11.4	309
20	Ovarian Leydig Cell Hyperplasia: An Unusual Case of Virilization in a Postmenopausal Woman. <i>Case Reports in Endocrinology</i> , 2014, 2014, 1-4.	0.4	8
21	SGLT2 Inhibitors to Control Glycemia in Type 2 Diabetes Mellitus: A New Approach to an Old Problem. <i>Postgraduate Medicine</i> , 2014, 126, 111-117.	2.0	22
22	Comment and response to: dapagliflozin “do we need it registered for type 2 diabetes?”. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2751-2753.	1.8	0
23	Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. <i>Diabetes Care</i> , 2014, 37, 740-750.	8.6	234
24	Targeting Renal Glucose Reabsorption for the Treatment of Type 2 Diabetes Mellitus Using the SGLT2 Inhibitor Dapagliflozin. <i>Postgraduate Medicine</i> , 2012, 124, 62-73.	2.0	12
25	Advantages of Extended-Release Metformin in Patients with Type 2 Diabetes Mellitus. <i>Postgraduate Medicine</i> , 2011, 123, 15-23.	2.0	54
26	Skin manifestations of hormone-secreting tumors. <i>Dermatologic Therapy</i> , 2010, 23, 643-650.	1.7	34
27	The Importance of Reducing Hyperglycemia While Preserving Insulin Secretion”The Rationale for Sodium-coupled Glucose Co-transporter 2 Inhibition in Diabetes. <i>US Endocrinology</i> , 2009, 05, 75.	0.3	4
28	Rare syndromes. <i>Clinics in Dermatology</i> , 2006, 24, 299-316.	1.6	34
29	Endocrinology in dermatology. <i>Clinics in Dermatology</i> , 2006, 24, 235-236.	1.6	2
30	Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2004, 20, 565-572.	1.9	111
31	Cutaneous Manifestations of Endocrine Disorders. <i>American Journal of Clinical Dermatology</i> , 2003, 4, 315-331.	6.7	181
32	Use of an anaerobic environment to preserve the endogenous activity of protein tyrosine phosphatases isolated from intact cells. <i>FASEB Journal</i> , 2001, 15, 1637-1639.	0.5	20
33	ENDOCRINOLOGIC EMERGENCIES IN DERMATOLOGY. , 0, , 298-312.		0